Rajesh Ranganathan, PhD Director of Translational Medicine Initiatives and Clinical Partnerships Contact by email
Dr. Rajesh Ranganathan is the Director of Translational Medicine Initiatives and Clinical Partnerships at Massachusetts General Hospital. In this role, Dr. Ranganathan he conducts business development that culminates in clinical studies being conducted at the Translational Research Center. He is also contributing to the translational research training programs that will be offered to a range of trainees.
Additionally, Dr. Ranganathan is builkding partnerships within and external to Mass General, including with industry, to conduct preclinical research to elucidate the causes of serious and perplexing ailments that defy a definitive diagnosis or are refractory to existing treatments.
Previously, he served for one year as the Vice President of Science and Regulatory Advocacy at PhRMA (Pharmaceutical Researchers and Manufacturers of America) in Washington DC.
Prior to his time at PhRMA, for 3+ years, Dr. Ranganathan was the Director of the Office of Translational Research at the National Institutes for Neurological Disorders and Stroke (NINDS) at the NIH. He transitioned to this role at NINDS after serving as the Senior Advisor to the NIH Director for Translational Medicine for 15 months.
He joined the NIH in Nov. 2010 after spending 7+ years at the Novartis Institutes for Biomedical Research Inc. in Cambridge, MA, where he was a director in the scientific strategy and portfolio management group and also founded and led a Global Office of Scientific Education for the Institutes.
Dr. Ranganathan received his Bachelor’s Degrees in Biology and Chemistry from Amherst College, performed his doctoral training with Dr. H. Robert Horvitz at MIT in C. elegans neurobiology, and his postdoctoral training with Dr. Linda Buck at Harvard Medical School and the Fred Hutchinson Cancer Research Center in the area of mammalian sensory regulation.
|